Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases

Launched by JINLING HOSPITAL, CHINA · Sep 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called hyperbaric oxygen therapy (HBOT) to see if it can help adults with a liver condition known as Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD). The researchers want to find out if HBOT can reduce the fat in the liver and improve liver function and overall health for people with this condition. Participants in the trial will either receive HBOT 20 times over the course of a month or get a regular medication. They will also have check-ups and tests at the beginning and end of the treatment, as well as six months after the therapy.

To join this trial, participants need to have MASLD, but there are some important criteria to consider. For instance, people who have serious liver diseases, severe organ issues, or who are pregnant cannot participate. Additionally, those who have had certain treatments or surgeries recently, or who are unable to cope with the enclosed space of the hyperbaric chamber, are also excluded. This trial is currently looking for participants of all genders, aged 18 to 80, who are interested in exploring a new potential treatment for their liver condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Metabolic dysfunction-associated steatotic liver disease patients
• Exclusion Criteria:
• • Participants are unfit for hyperbaric treatment.
• • Participants with prior oxygen therapy within the last 6 months.
• • Participants with history of viral hepatitis, hemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency.
• • Participants with severe organ dysfunctions or malignant tumors.
• • Participants have weight loss plan or major operations within the last 6 months.
• • Participants are unable to provide informed consent or currently participating in or has within the last 3 months participated in any other clinical trial.
• • Participants are pregnant or lactating.
• • Participants with claustrophobia or that cannot decompress properly.